NEW YORK (GenomeWeb) – MDxHealth reported today that its fourth quarter revenues rose 68 percent percent year over year, driven largely by higher sales of its ConfirmMDx prostate cancer test.

For the three months ended Dec. 31, 2015, MDxHealth reported revenues of $5.7 million compared to $3.4 million in Q4 2014.

Sales of the ConfirmMDx test represented 86 percent of the quarter's total revenues compared to 70 percent of revenues in Q4 2014. The increase was also due in part to royalty and milestone payments from Exact Sciences.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.